Belimumab for the Treatment of Early Diffuse Systemic Sclerosis
Jessica K. Gordon MD MSc1, Viktor Martyanov PhD2, Jennifer M. Franks2,
Elana J. Bernstein MD3, Jackie Szymonifka MS4, Cynthia Magro MD5,
Horatio F. Wildman MD6, Tammara A. Wood MS2, Michael L. Whitfield2,
Robert F. Spiera MD1
1Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH,
2Department of Rheumatology, Hospital for Special Surger, New York, NY,
3Quantitative Biomedical Sciences, Geisel School of Medicine at Dartmouth, Hanover, NH,
4Department of Rheumatology, New York Presbyterian Hospital-Columbia, New York, NY,
5Department of Biostatistics, Hospital for Special Surgery, New York, NY,
6Department of Pathology, Weill-cornell Medical college, New York, NY,
7Department of Dermatology, Weill-Cornell Medical College, New York, NY
Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Trial
DOI: 10.1002/art.40358
Gene Expression Analyses